Labcorp, a global life sciences company, has formed Fortrea, a spin-off of its clinical development business.
Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global Contract Research Organization (CRO), that offers comprehensive drug and medical device development services.
Fortrea will employee more that 19,000 people, and provide Phase I through IV clinical trial management, and commercialization solutions to pharmaceutical and biotechnology organizations around the world.
